Inhibition of HDAC2 protects the retina from ischemic injury

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 6, 2013, Pages 4072-4080

  Fan, Jie ^a   Alsarraf, Oday ^a   Dahrouj, Mohammad ^a   Platt, Kenneth A ^b   Chou, C James ^c   Rice, Dennis S ^b   Crosson, Craig E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b LEXICON PHARMACEUTICALS INC   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

HDAC2; Ischemia; Neuroprotection; Retinal degeneration

Indexed keywords

HISTONE DEACETYLASE 2; TRICHOSTATIN A;

A WAVE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B WAVE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ELECTRORETINOGRAPHY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETINA DEGENERATION; RETINA GANGLION CELL; RETINA ISCHEMIA; SOUTHERN BLOTTING;

HDAC2; ISCHEMIA; NEUROPROTECTION; RETINAL DEGENERATION;

ANIMALS; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REPERFUSION INJURY; RETINA; RETINAL DEGENERATION; RETINAL GANGLION CELLS;

EID: 84878973316     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11529     Document Type: Article

References (44)

1. Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 2000;408:377-381.
2. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? Embo J. 2000;19:1176-1179.
3. Sterner DE, Berger SL. Acetylation of histones and transcription- related factors. Microbiol Mol Biol Rev. 2000;64:435-459.
4. Yang XJ. Lysine acetylation and the bromodomain: a new partnership for signaling. Bioessays. 2004;26:1076-1087.
5. Huang L. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol. 2006;209: 611-616.
6. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 2002;110:479-488.
7. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010;3:5.
8. Wagner JM, Hackanson B, Lubbert M, Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics. 2010;1:117-136.
9. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci. 2003;23:9418-9427.
10. Gardian G, Browne SE, Choi DK, et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem. 2005;280:556-563.
11. Oliveira JM, Chen S, Almeida S, et al. Mitochondrial-dependent Ca2{thorn} handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J Neurosci. 2006;26:11174-11186.
12. Petri S, Kiaei M, Kipiani K, et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2006;22:40-49.
13. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A. 2001;98:9808-9813.
14. Faraco G, Pancani T, Formentini L, et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol. 2006;70: 1876-1884.
15. Crosson CE, Mani SK, Husain S, Alsarraf O, Menick DR. Inhibition of histone deacetylase protects the retina from ischemic injury. Invest Ophthalmol Vis Sci. 2010;51:3639-3645.
16. Chen B, Cepko CL. Requirement of histone deacetylase activity for the expression of critical photoreceptor genes. BMC Dev Biol. 2007;7:78.
17. Schwechter BR, Millet LE, Levin LA. Histone deacetylase inhibition-mediated differentiation of RGC-5 cells and interaction with survival. Invest Ophthalmol Vis Sci. 2007;48:2845-2857.
18. Guan JS, Haggarty SJ, Giacometti E, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459:55-60.
19. Kilgore M, Miller CA, Fass DM, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacol. 2010;35:870-880.
20. Durham B. Novel histone deacetylase (HDAC) inhibitors with improved selectivity for HDAC2 and HDAC3 protect against neural cell death. Biosci Horiz. 2012;5:1-7.
21. Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 2007;21:1790-1802.
22. Husain S, Potter DE, Crosson CE. Opioid receptor-activation: retina protected from ischemic injury. Invest Ophthalmol Vis Sci. 2009;50:3853-3859.
23. Fan J, Rohrer B, Moiseyev G, Ma JX, Crouch RK. Isorhodopsin rather than rhodopsin mediates rod function in RPE65 knockout mice. Proc Natl Acad Sci U S A. 2003;100:13662-13667.
24. Wegener D, Wirsching F, Riester D, Schwienhorst A. sA fluorogenic histone deacetylase assay well suited for highthroughput activity screening. Chem Biol. 2003;10:61-68.
25. Walkinshaw DR, Tahmasebi S, Bertos NR, Yang XJ. Histone deacetylases as transducers and targets of nuclear signaling. J Cell Biochem. 2008;104:1541-1552.
26. Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG. Histone acetylation and the cell-cycle in cancer. Front Biosci. 2001;6:D610-D629.
27. Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene. 2012;31:537-551.
28. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009;32:591-601.
29. Saha RN, Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ. 2006;13:539-550.
30. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007; 5:981-989.
31. Abel T, Zukin RS. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol. 2008;8:57-64.
32. Chen B, Cepko CL. HDAC4 regulates neuronal survival in normal and diseased retinas. Science. 2009;323:256-259.
33. Biermann J, Grieshaber P, Goebel U, et al. Valproic acidmediated neuroprotection and regeneration in injured retinal ganglion cells. Invest Ophthalmol Vis Sci. 2010;51:526-534.
34. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem. 2004;89:1358-1367.
35. Nasu Y, Nishida K, Miyazawa S, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibodyinduced arthritis mouse model. Osteoarthritis Cartilage. 2008;16:723-732.
36. Quivy V, Van Lint C. Regulation at multiple levels of NFkappaB- mediated transactivation by protein acetylation. Biochem Pharmacol. 2004;68:1221-1229.
37. Wang X, Song Y, Jacobi JL, Tuan RS. Inhibition of histone deacetylases antagonized FGF2 and IL-1beta effects on MMP expression in human articular chondrocytes. Growth Factors. 2009;27:40-49.
38. Yang XJ, Gregoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol. 2005;25:2873-2884.
39. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005;307:269-273.
40. Chang HH, Chiang CP, Hung HC, Lin CY, Deng YT, Kuo MY. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol. 2009;45:610-614.
41. Fritzsche FR, Weichert W, Roske A, et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer. 2008;8:381.
42. Ropero S, Fraga MF, Ballestar E, et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet. 2006;38:566-569.
43. Weichert W, Roske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008;98:604-610.
44. Janssen C, Schmalbach S, Boeselt S, Sarlette A, Dengler R, Petri S. Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2010;69:573-581.